Skip to main content
ANAB
NASDAQ Life Sciences

Officer Dennis Mulroy Files to Sell Additional $1.03M in Stock, Continuing Recent Trend

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$51.33
Mkt Cap
$1.494B
52W Low
$11.402
52W High
$72.36
52W Position info
350% above low
Off High info
29% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

ANAB has more than doubled off its 52-week low of $11.402 on light trading volume (0.2× avg).

Summary

Officer Dennis Mulroy has filed to sell an additional $1.03 million in company stock, extending a recent pattern of significant insider selling that totals over $8.8 million in the last three months.


Key Events · Ownership and Investor Activity · ANAB

  • Officer Files Intent to Sell

    Officer Dennis Mulroy has filed a Form 144 indicating intent to sell 20,000 shares of common stock, with an approximate market value of $1,035,438.00.

  • Continuation of Selling Pattern

    This filing is the latest in a series of sales by Dennis Mulroy, who has sold a cumulative total of 138,422 shares, generating gross proceeds of $7,797,889.52, in the past three months, in addition to this proposed sale.

  • Option Exercise and Sale

    The shares to be sold were acquired through a stock option exercise on the same day as the proposed sale date, indicating a liquidity event rather than a direct open-market sale of previously held shares.

  • Conflicting Capital Allocation Signals

    The ongoing insider selling by an officer contrasts with the company's recent announcement of a $100 million share repurchase program, creating mixed signals regarding capital allocation and insider confidence.


Analysis · ANAB · Life Sciences

Officer Dennis Mulroy has filed to sell an additional $1.03 million worth of common stock. This transaction is part of a sustained pattern of insider selling by Mulroy, who has sold over $8.8 million in shares over the past three months. This ongoing distribution by a key officer, often involving the exercise of stock options followed by immediate sale, presents a negative signal, especially as it occurs after the company announced a $100 million share repurchase program.

At the time of this filing, ANAB was trading at $51.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $11.40 to $72.36. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANAB - Latest Insights

ANAB
Jun 29, 2026, 4:15 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $65.97
Real-time Price: $50.05 info
Change: -$15.92 (-24%) info
Market Cap: $1.489B info
ANAB
Jun 26, 2026, 4:46 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $63.15
Real-time Price: $50.05 info
Change: -$13.10 (-21%) info
Market Cap: $1.489B info
ANAB
Jun 22, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $59.32
Real-time Price: $50.05 info
Change: -$9.27 (-16%) info
Market Cap: $1.489B info
ANAB
Jun 17, 2026, 4:29 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $56.77
Real-time Price: $50.05 info
Change: -$6.72 (-12%) info
Market Cap: $1.489B info
ANAB
Jun 16, 2026, 5:28 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $57.60
Real-time Price: $50.05 info
Change: -$7.55 (-13%) info
Market Cap: $1.489B info